Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Crown Reserve Acquisition Corp. ICRAC · Entity 6210 | Director · CEO | September 26, 2025 | October 23, 2025 |
| DataMeds AI, Inc.WGRX · Entity 8434 | Director · Chief Executive Officer | June 22, 2026 | June 25, 2026 |
| Scienture Holdings, Inc.MEDS · Entity 7802 | Director · Interim CFO and Director | January 05, 2024 | May 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Crown Reserve Acquisition Corp. I
Report date September 26, 2025 · Filed October 23, 2025
This filing explicitly reported no securities owned.
DataMeds AI, Inc.
Report date June 22, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 282,365 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Other · Acquired 100,000 · Balance 282,365 F1: Represents the conversion of warrants (the "Warrants") issued to the Reporting Person on 3/31/2026 in lieu of cash compensation due to the Reporting Person. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2031-03-31 | Direct | 0 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Other · Acquired 100,000 · Balance 0 F2: Reflects the aggregate amount of Common Stock held by the Reporting Person following the Issuer's reverse stock split, effective May 26, 2026, as well as the Common Stock issued pursuant to the conversion of the Warrants. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the conversion of warrants (the "Warrants") issued to the Reporting Person on 3/31/2026 in lieu of cash compensation due to the Reporting Person.
F2: Reflects the aggregate amount of Common Stock held by the Reporting Person following the Issuer's reverse stock split, effective May 26, 2026, as well as the Common Stock issued pursuant to the conversion of the Warrants.
Scienture Holdings, Inc.
Report date January 05, 2024 · Filed May 28, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,242 |
Reported balance
After 2024-01-05 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-01-05 · Grant · Acquired 10,000 · Balance 112,242 F1: This Form 4/A is being filed to amend the previous Form 4 filed by Mr. Patel on January 16, 2024 (the "Prior Form 4"). The purpose of this Form 4/A is to: (i) correct the number of securities acquired on or about January 5, 2024; (ii) correct the amount of securities beneficially owned by Mr. Patel as of that date; and (iii) correct Mr. Patel's form of ownership. F2: The shares were granted as consideration for services rendered by Mr. Patel. F3: These securities are owned directly by Mr. Patel. |
| Common StockSEC Table I · non-derivative | IndirectBy Rina Patel (Spouse) | 27,778 |
Reported balance
Holding disclosure · report date 2024-01-05 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance 27,778 F4: These securities are owned directly by Rina Patel, Mr. Patel's wife. By nature of their spousal relationship, Mr. Patel is deemed to be the indirect beneficial owner of the shares held by Mrs. Patel. |
| Common StockSEC Table I · non-derivative | IndirectBy Patel Trust | 36,667 |
Reported balance
Holding disclosure · report date 2024-01-05 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance 36,667 F5: These securities are owned directly by the Patel Trust. Mr. Patel is the trustee of the Patel Trust and, in such capacity, is deemed to be the indirect beneficial owner of the shares held by the Patel Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4/A is being filed to amend the previous Form 4 filed by Mr. Patel on January 16, 2024 (the "Prior Form 4"). The purpose of this Form 4/A is to: (i) correct the number of securities acquired on or about January 5, 2024; (ii) correct the amount of securities beneficially owned by Mr. Patel as of that date; and (iii) correct Mr. Patel's form of ownership.
F2: The shares were granted as consideration for services rendered by Mr. Patel.
F3: These securities are owned directly by Mr. Patel.
F4: These securities are owned directly by Rina Patel, Mr. Patel's wife. By nature of their spousal relationship, Mr. Patel is deemed to be the indirect beneficial owner of the shares held by Mrs. Patel.
F5: These securities are owned directly by the Patel Trust. Mr. Patel is the trustee of the Patel Trust and, in such capacity, is deemed to be the indirect beneficial owner of the shares held by the Patel Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 25, 2026 20:57 UTC | DataMeds AI, Inc. WGRX · Entity 8434 | OtherWarrant · Derivative | 100,000 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001493152-26-030151 · ownership.xml · derivative · entry 2 Patel Prashant · CIK 0001617460 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2031-03-31 F2 · shares: Reflects the aggregate amount of Common Stock held by the Reporting Person following the Issuer's reverse stock split, effective May 26, 2026, as well as the Common Stock issued pursuant to the conversion of the Warrants. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 20:57 UTC | DataMeds AI, Inc. WGRX · Entity 8434 | OtherCommon Stock | 100,000 | $0.01 | $500.00 |
DisclosureSEC source: 0001493152-26-030151 · ownership.xml · nonDerivative · entry 1 Patel Prashant · CIK 0001617460 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,365 F1 · shares: Represents the conversion of warrants (the "Warrants") issued to the Reporting Person on 3/31/2026 in lieu of cash compensation due to the Reporting Person. Read SEC document |
| March 31, 2026 Filed Apr 24, 2026 00:55 UTC | DataMeds AI, Inc. WGRX · Entity 8434 | GrantWarrant · Derivative | 5,000,000 | $0.01 Strike: $0.01 | $50,000.00 |
DisclosureSEC source: 0001493152-26-018820 · ownership.xml · derivative · entry 2 Patel Prashant · CIK 0001617460 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Common Stock · 5,000,000 shares Expires 2031-03-31 F2 · shares: The Issuer issued the Reporting Person 5,000,000 warrants to purchase common stock (the "Warrants") as compensation for the Reporting Person's service to the Issuer. The Warrants were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Read SEC document |
| March 31, 2026 Filed Apr 24, 2026 00:55 UTC | DataMeds AI, Inc. WGRX · Entity 8434 | GrantCommon Stock | 5,000,000 | $0.20 | $1,000,000.00 |
DisclosureSEC source: 0001493152-26-018820 · ownership.xml · nonDerivative · entry 1 Patel Prashant · CIK 0001617460 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,118,247 F1 · shares: The Issuer issued the Reporting Person 5,000,000 shares of common stock (the "Shares") as compensation for the Reporting Person's service to the Issuer. The Shares were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Read SEC document |
| March 31, 2026 Filed Jun 25, 2026 20:15 UTC Amendment | DataMeds AI, Inc. WGRX · Entity 8434 | GrantWarrant · Derivative | 5,000,000 | $0.00 Strike: $0.00 | $500.00 |
DisclosureSEC source: 0001493152-26-030122 · ownership.xml · derivative · entry 2 Patel Prashant · CIK 0001617460 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Common Stock · 5,000,000 shares Expires 2031-03-31 F2 · shares: The Issuer issued the Reporting Person 5,000,000 warrants to purchase common stock (the "Warrants") as compensation for the Reporting Person's service to the Issuer. The Warrants were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Read SEC document |
| March 31, 2026 Filed Jun 25, 2026 20:15 UTC Amendment | DataMeds AI, Inc. WGRX · Entity 8434 | GrantCommon Stock | 5,000,000 | $0.20 | $1,000,000.00 |
DisclosureSEC source: 0001493152-26-030122 · ownership.xml · nonDerivative · entry 1 Patel Prashant · CIK 0001617460 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,118,247 F1 · shares: The Issuer issued the Reporting Person 5,000,000 shares of common stock (the "Shares") as compensation for the Reporting Person's service to the Issuer. The Shares were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 16:02 UTC | DataMeds AI, Inc. WGRX · Entity 8434 | GrantCommon Stock, Par Value $0.0001 | 700,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-000555 · ownership.xml · nonDerivative · entry 3 Patel Prashant · CIK 0001617460 · Director · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Scietech LLC Disclosed balance after: 700,000 F1 · shares: Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 16:02 UTC | DataMeds AI, Inc. WGRX · Entity 8434 | GrantCommon Stock, Par Value $0.0001 | 1,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-000555 · ownership.xml · nonDerivative · entry 2 Patel Prashant · CIK 0001617460 · Director · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Akrias LLC Disclosed balance after: 1,500,000 F1 · shares: Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 16:02 UTC | DataMeds AI, Inc. WGRX · Entity 8434 | GrantCommon Stock, Par Value $0.0001 | 1,882,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-000555 · ownership.xml · nonDerivative · entry 1 Patel Prashant · CIK 0001617460 · Director · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,118,247 F1 · shares: Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. Read SEC document |
| January 05, 2024 Filed Jan 16, 2024 11:12 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | GrantCommon stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-002319 · ownership.xml · nonDerivative · entry 1 Patel Prashant · CIK 0001617460 · Director · Interim CFO and Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Patel Trust 2010 Disclosed balance after: 150,000 F1 · shares: Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/2 of the shares on January 1, 2023 and April 1, 2023, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d). F2 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors. F3 · ownership.nature: These securities are owned directly by the Patel Trust 2010, of which Mr. Patel is the trustee. Mr. Patel, as the trustee, is deemed to have indirect beneficial ownership of the shares held by the Patel Trust 2010. Read SEC document |
| January 05, 2024 Filed May 28, 2024 20:59 UTC Amendment | Scienture Holdings, Inc. MEDS · Entity 7802 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-021627 · ownership.xml · nonDerivative · entry 1 Patel Prashant · CIK 0001617460 · Director · Interim CFO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,242 F1 · kind: This Form 4/A is being filed to amend the previous Form 4 filed by Mr. Patel on January 16, 2024 (the "Prior Form 4"). The purpose of this Form 4/A is to: (i) correct the number of securities acquired on or about January 5, 2024; (ii) correct the amount of securities beneficially owned by Mr. Patel as of that date; and (iii) correct Mr. Patel's form of ownership. F2 · price: The shares were granted as consideration for services rendered by Mr. Patel. F3 · ownership.direct: These securities are owned directly by Mr. Patel. Read SEC document |
| September 01, 2022 Filed Sep 16, 2022 21:20 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | GrantCommon stock | 8,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-026120 · ownership.xml · nonDerivative · entry 1 Patel Prashant · CIK 0001617460 · Director · President and COO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,261,120 F1 · shares: Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on September 30, 2022, October 31, 2022, November 30, 2022 and December 31, 2022, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d). F2 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as President and Chief Operating Officer. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 20:53 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | SaleCommon stock | 7,500 | $4.39 | $32,909.25 |
DisclosureSEC source: 0001493152-21-009261 · ownership.xml · nonDerivative · entry 1 Patel Prashant · CIK 0001617460 · Director · President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,252,500 F1 · shares: The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person, to satisfy the Reporting Person's tax liability in connection with the April 2021 vesting of certain restricted stock shares which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3. F2 · price: Represents the weighted sales price for all sales made on April 19, 2021, which were made in a range of between $4.30 and $4.77 per share. The Reporting Person will provide to the Commission, the Issuer or any stockholder, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 16:59 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | SaleCommon stock | 7,500 | $5.29 | $39,702.75 |
DisclosureSEC source: 0001493152-20-023728 · ownership.xml · nonDerivative · entry 1 Patel Prashant · CIK 0001617460 · Director · President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260,000 F1 · shares: The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person, to satisfy the Reporting Person's tax liability in connection with the December 2020 vesting of certain restricted stock shares which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3. F2 · price: Represents the weighted sales price for all sales made on December 14, 2020, which were made in a range of between $5.22 and $5.34 per share. The Reporting Person will provide to the Commission, the Issuer or any stockholder, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 14, 2020 Filed Jul 21, 2020 23:28 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | SaleCommon stock | 7,000 | $5.44 | $38,080.00 |
DisclosureSEC source: 0001493152-20-013735 · ownership.xml · nonDerivative · entry 2 Patel Prashant · CIK 0001617460 · Director · President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,267,500 F1 · shares: The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person to satisfy the Reporting Person's tax liability in connection with the April 2020 grant of certain restricted stock which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3(b). F2 · price: Represents the weighted sales price for all sales made on July 14, 2020, which were made in a range of between ($5.31) and ($5.55) per share. The Reporting Person will provide to the Commission, the Issuer or any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 21, 2020 23:28 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | SaleCommon stock | 500 | $5.71 | $2,855.00 |
DisclosureSEC source: 0001493152-20-013735 · ownership.xml · nonDerivative · entry 1 Patel Prashant · CIK 0001617460 · Director · President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,274,500 F1 · shares: The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person to satisfy the Reporting Person's tax liability in connection with the April 2020 grant of certain restricted stock which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3(b). Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 10:31 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | GrantCommon stock | 50,000 | $6.12 | $306,000.00 |
DisclosureSEC source: 0001493152-20-006510 · ownership.xml · nonDerivative · entry 1 Patel Prashant · CIK 0001617460 · Director · President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,255,000 F1 · shares: Shares are fully earned as of April 14, 2020, The table above includes the full amount of such shares which are fully earned by the Reporting Person as of April 14, 2020, even though such shares have not been issued as of the date of this report. F2 · price: Issued to the Reporting Person as a compensation bonus for 2019. Exempt under Rule 16b-3(d). Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:47 UTC | Scienture Holdings, Inc. TRXD · Entity 7802 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001078782-19-000429 · primary_doc.xml · derivative · entry 1 Patel Prashant · CIK 0001617460 · Director · President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250,000 Underlying: Common Stock · 100,000 shares Expires 2019-05-13 F1 · derivative.exercise_date: Option vests and becomes exercisable quarterly over four years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.